Profile data is unavailable for this security.
About the company
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.
- Revenue in NZD (TTM)174.51m
- Net income in NZD11.02m
- Incorporated1997
- Employees100.00
- LocationAFT Pharmaceuticals LtdLevel 1, 129 Hurstmere RoadAUCKLAND 0622New ZealandNZL
- Phone+64 94880232
- Fax+64 94880234
- Websitehttp://www.aftpharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dali Pharmaceutical Co Ltd | 15.04m | -5.23m | 284.66m | 272.00 | -- | 3.31 | -- | 18.93 | -0.104 | -0.104 | 0.2991 | 1.71 | 0.1381 | 1.15 | 15.89 | 241,555.10 | -4.80 | -2.31 | -5.61 | -2.77 | 22.16 | 65.39 | -34.78 | -7.00 | 3.11 | -- | 0.0593 | -- | -34.06 | -26.30 | -13.16 | -- | 16.34 | -- |
Essex Bio-Technology Ltd | 361.74m | 58.35m | 286.32m | 1.48k | 5.08 | 0.7022 | 4.03 | 0.7915 | 0.4689 | 0.4689 | 2.87 | 3.39 | 0.6161 | 2.28 | 3.35 | 1,152,300.00 | 9.94 | 11.20 | 13.21 | 14.73 | 90.20 | 86.01 | 16.13 | 19.77 | 1.46 | -- | 0.1326 | 16.16 | 29.51 | 7.72 | 22.11 | 3.56 | 7.29 | 7.39 |
Cuorips Inc | 422.25k | -6.34m | 292.27m | 46.00 | -- | 4.52 | -- | 692.18 | -76.49 | -76.49 | 5.13 | 766.30 | 0.0081 | 3.93 | 39.73 | 867,130.40 | -12.10 | -- | -12.39 | -- | 45.79 | -- | -1,500.91 | -- | 35.89 | -- | 0.00 | -- | 175.12 | -- | -20.45 | -- | -- | -- |
Hester Biosciences Ltd | 58.03m | 3.66m | 292.86m | 693.00 | 77.01 | -- | 37.59 | 5.05 | 22.54 | 22.54 | 352.21 | -- | -- | -- | -- | 4,222,078.00 | -- | 8.22 | -- | 10.27 | 67.10 | 69.31 | 7.00 | 16.15 | -- | 2.15 | -- | 22.67 | 13.23 | 14.30 | -32.28 | 0.7733 | 27.62 | -4.36 |
Bangkok Lab and Cosmetic PCL | 63.60m | 6.58m | 293.10m | 698.00 | 13.57 | 2.06 | 31.82 | 4.61 | 0.3979 | 0.3979 | 3.05 | 2.63 | 0.8145 | 2.43 | 4.34 | 2,014,590.00 | 8.74 | 6.01 | 13.33 | 13.28 | 31.46 | 27.33 | 10.73 | 5.68 | 3.06 | 7.77 | 0.1732 | -- | 8.50 | 17.54 | 15.65 | 51.84 | 19.54 | -- |
AFT Pharmaceuticals Ltd | 174.51m | 11.02m | 293.63m | 100.00 | 26.65 | 3.97 | 23.36 | 1.68 | 0.1051 | 0.1051 | 1.66 | 0.7048 | 1.22 | 2.00 | 5.67 | 1,745,050.00 | 7.73 | 10.00 | 12.48 | 15.59 | 45.98 | 46.12 | 6.31 | 8.22 | 0.8372 | 5.99 | 0.3566 | 0.00 | 20.20 | 14.05 | -46.32 | -- | 26.32 | -- |
CStone Pharmaceuticals | 106.41m | -84.25m | 293.99m | 230.00 | -- | 2.81 | -- | 2.76 | -0.3151 | -0.3151 | 0.3974 | 0.385 | 0.2811 | 2.44 | 3.72 | 2,182,570.00 | -22.25 | -54.76 | -48.85 | -81.68 | 65.60 | -- | -79.17 | -301.62 | 1.44 | -- | 0.4431 | -- | -3.64 | -- | 59.32 | -- | 52.42 | -- |
Ngl Fine Chem Ltd | 62.87m | 7.54m | 294.15m | 343.00 | 39.02 | -- | 29.83 | 4.68 | 61.52 | 61.52 | 513.13 | -- | -- | -- | -- | 9,241,813.00 | -- | 15.74 | -- | 20.73 | 53.94 | 45.27 | 11.99 | 13.43 | -- | 34.92 | -- | 3.47 | -12.42 | 19.17 | -58.92 | 10.23 | 5.65 | -- |
Ascletis Pharma Inc | 12.98m | -33.20m | 304.84m | 219.00 | -- | 0.5842 | -- | 23.48 | -0.1472 | -0.1472 | 0.057 | 2.43 | 0.022 | 2.30 | 3.86 | 279,684.00 | -5.62 | -6.43 | -5.91 | -6.64 | 45.92 | 35.67 | -255.70 | -243.38 | 16.54 | -6.09 | 0.0036 | -- | 4.63 | -19.39 | 54.04 | -- | -20.44 | -- |
Holder | Shares | % Held |
---|---|---|
Accident Compensation Corp.as of 30 Apr 2023 | 4.86m | 4.63% |
Guardians of New Zealand Superannuationas of 30 Apr 2023 | 1.69m | 1.62% |
FCA Corp.as of 31 Mar 2024 | 46.00k | 0.04% |
Dimensional Fund Advisors LPas of 04 Apr 2024 | 39.19k | 0.04% |
Acadian Asset Management LLCas of 30 Sep 2023 | 4.43k | 0.00% |